Exciting news! We are happy to share our recent publication “Application of platform process development approaches to the manufacturing of Mabcalin™ bispecifics” in the Journal of Biotechnology. This paper is the result of a successful collaboration between colleagues from Pieris Pharmaceuticals and KBI Biopharma. It discusses the manufacturing challenges of bispecific biotherapeutics and the development of a robust high-yield manufacturing platform for Mabcalin™ molecules providing data up to commercially relevant scales. The collaborative effort underscores the platform's efficiency and cost-effectiveness, with significant implications for the immune-oncology field. Check out the open access article on ScienceDirect:
About us
Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB bispecifics immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. In addition to the milestone potential, Pieris would be eligible for sales royalties on the same partnered programs if they ultimately are approved for commercialization. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. For more information, visit www.pieris.com.
- Website
-
http://www.pieris.com/
External link for Pieris Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2001
- Specialties
- IO Bispecific
Locations
-
Primary
Get directions
225 Franklin Street
Boston, Massachusetts 02110, US
-
Get directions
Zeppelinstraße 3
Hallbergmoos, Bavaria 85399, DE